Literature DB >> 17647287

Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.

Miriam M Treggiari1, Margaret Rosenfeld, George Retsch-Bogart, Ron Gibson, Bonnie Ramsey.   

Abstract

The primary cause of morbidity and mortality in children with cystic fibrosis (CF) is the progression of obstructive lung disease secondary to chronic endobronchial infection, mainly caused by Pseudomonas aeruginosa (Pa). Initial Pa isolates are typically non-mucoid, usually susceptible to most anti-pseudomonal antibiotics, and potentially amenable to eradication. Preliminary studies of early intervention suggest a "window of opportunity" with anti-pseudomonal antibiotics to eradicate Pa from upper and lower airways. Several large trials in young children with CF are currently ongoing with the goals of (1) investigating if early intervention at the time of initial Pa acquisition is effective and safe and (2) identifying the least invasive and safest treatment regimen to achieve both microbiologic and clinical benefits. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17647287     DOI: 10.1002/ppul.20665

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  23 in total

1.  Role of Nitric Oxide-Releasing Chitosan Oligosaccharides on Mucus Viscoelasticity.

Authors:  Katelyn P Reighard; Camille Ehre; Zachary L Rushton; Mona Jasmine R Ahonen; David B Hill; Mark H Schoenfisch
Journal:  ACS Biomater Sci Eng       Date:  2017-05-15

2.  Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.

Authors:  Timothy J Bensman; Joshua Wang; Jordanna Jayne; Lynn Fukushima; Adupa P Rao; David Z D'Argenio; Paul M Beringer
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic Fibrosis Pseudomonas aeruginosa.

Authors:  Rafah Allobawi; Drishti P Ghelani; Elena K Schneider-Futschik
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-27

4.  Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study.

Authors:  Matthew R Crull; Ranjani Somayaji; Kathleen J Ramos; Ellen Caldwell; Nicole Mayer-Hamblett; Moira L Aitken; David P Nichols; Ali Rowhani-Rahbar; Christopher H Goss
Journal:  Clin Infect Dis       Date:  2018-09-14       Impact factor: 9.079

Review 5.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

Review 6.  Newborn screening for cystic fibrosis.

Authors:  Jack K Sharp; Michael J Rock
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

7.  Progress in cystic fibrosis and the CF Therapeutics Development Network.

Authors:  Steven M Rowe; Drucy S Borowitz; Jane L Burns; John P Clancy; Scott H Donaldson; George Retsch-Bogart; Scott D Sagel; Bonnie W Ramsey
Journal:  Thorax       Date:  2012-10       Impact factor: 9.139

8.  Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients.

Authors:  Timothy J Kidd; Kay A Ramsay; Honghua Hu; Peter T P Bye; Mark R Elkins; Keith Grimwood; Colin Harbour; Guy B Marks; Michael D Nissen; Philip J Robinson; Barbara R Rose; Theo P Sloots; Claire E Wainwright; Scott C Bell
Journal:  J Clin Microbiol       Date:  2009-03-04       Impact factor: 5.948

9.  Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.

Authors:  Hara Levy; Leslie A Kalish; Carolyn L Cannon; K Christopher García; Craig Gerard; Don Goldmann; Gerald B Pier; Scott T Weiss; A A Colin
Journal:  Pediatr Pulmonol       Date:  2008-05

10.  Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Miriam M Treggiari; Michael W Konstan; George Retsch-Bogart; Wayne Morgan; Jeff Wagener; Ronald L Gibson; Umer Khan; Julia Emerson; Valeria Thompson; Eric P Elkin; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2013-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.